RxDoctor Payments Data

Francisco Valedon, MD

Internal Medicine · Gastonia, NCNPI 1689661100

Payments from drug & device makers

$955in general payments, 2019–2025

Across 43 payments — averaging $22.22 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$461
  • Novo Nordisk$160
  • Biogen$87
  • Boston Scientific$36
  • Astellas Pharma US Inc$26
  • E.r. Squibb & Sons, L.L.C.$20
  • plus $166 from 11 others

What the payments were for

  • Food & beverage$955100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$955 in reported general payments places this provider in the 70th percentile of 3,302 internal medicine providers in North Carolina.

See all internal medicine providers in North Carolina

Medicare billing

Part B allowed, 2024
$86,647
Medicare patients
266
Services billed
1,624

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide131$135,786
XareltoRivaroxaban82$71,406
EliquisApixaban87$66,979
JardianceEmpagliflozin70$52,048
PercocetOxycodone Hcl/Acetaminophen11$49,513
TrulicityDulaglutide32$47,872
RybelsusSemaglutide21$25,814
MounjaroTirzepatide21$25,637
UbrelvyUbrogepant18$20,990
EntrestoSacubitril/Valsartan15$16,637
JanuviaSitagliptin Phosphate27$14,678
FarxigaDapagliflozin Propanediol14$14,572
TradjentaLinagliptin11$14,178
Tresiba Flextouch U-100Insulin Degludec24$13,458
Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog14$12,158

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic, Rybelsus$160$161,599152 claims
Lilly USA, LLCTrulicity, Mounjaro$20$73,50953 claims
PfizerEliquis, Paxlovid, Premarin$15$72,536122 claims
AbbVieUbrelvy$461$20,99018 claims
AstraZenecaFarxiga, Symbicort$18$19,13130 claims
NovartisEntresto$13$16,63715 claims
Astellas Pharma US IncMyrbetriq$26$11,80112 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 3,302 internal medicine providers in North Carolina.

Other internal medicine in Gastonia

See the full list for North Carolina

Where these figures come from

Is this you, or does something look wrong? →